Kim A H Nicolaije1, Nicole P M Ezendam1, M Caroline Vos1, Johanna M A Pijnenborg1, Dorry Boll1, Erik A Boss1, Ralph H M Hermans1, Karin C M Engelhart1, Joke E Haartsen1, Brenda M Pijlman1, Ingrid E A M van Loon-Baelemans1, Helena J M M Mertens1, Willem E Nolting1, Johannes J van Beek1, Jan A Roukema1, Wobbe P Zijlstra1, Roy F P M Kruitwagen1, Lonneke V van de Poll-Franse2. 1. Kim A.H. Nicolaije, Nicole P.M. Ezendam, Wobbe P. Zijlstra, and Lonneke V. van de Poll-Franse, Tilburg University, Tilburg; Kim A.H. Nicolaije, Nicole P.M. Ezendam, and Lonneke V. van de Poll-Franse, Comprehensive Cancer Center the Netherlands, Eindhoven; M. Caroline Vos and Dorry Boll, Elisabeth-TweeSteden Hospital, Tilburg and Waalwijk; Erik A. Boss, Maxima Medical Center, Veldhoven and Eindhoven, the Netherlands; Ralph H.M. Hermans, Catharina Hospital, Eindhoven; Karin C.M. Engelhart, St Anna Hospital, Geldrop and Eindhoven; Joke E. Haartsen, Elkerliek Hospital, Helmond; Brenda M. Pijlman, Jeroen Bosch Hospital, 's-Hertogenbosch; Ingrid E.A.M. van Loon- Baelemans, Amphia Hospital, Breda and Oosterhout; Helena J.M.M. Mertens, Orbis Medical Center, Sittard; Willem E. Nolting, St Jans Hospital, Weert; Johannes J. van Beek, VieCuri Hospital, Venlo and Venray; Jan A. Roukema, Tilburg University and Elisabeth-TweeSteden Hospital Tilburg; and Roy F.P.M. Kruitwagen, Maastricht University Medical Center, Maastricht, the Netherlands. 2. Kim A.H. Nicolaije, Nicole P.M. Ezendam, Wobbe P. Zijlstra, and Lonneke V. van de Poll-Franse, Tilburg University, Tilburg; Kim A.H. Nicolaije, Nicole P.M. Ezendam, and Lonneke V. van de Poll-Franse, Comprehensive Cancer Center the Netherlands, Eindhoven; M. Caroline Vos and Dorry Boll, Elisabeth-TweeSteden Hospital, Tilburg and Waalwijk; Erik A. Boss, Maxima Medical Center, Veldhoven and Eindhoven, the Netherlands; Ralph H.M. Hermans, Catharina Hospital, Eindhoven; Karin C.M. Engelhart, St Anna Hospital, Geldrop and Eindhoven; Joke E. Haartsen, Elkerliek Hospital, Helmond; Brenda M. Pijlman, Jeroen Bosch Hospital, 's-Hertogenbosch; Ingrid E.A.M. van Loon- Baelemans, Amphia Hospital, Breda and Oosterhout; Helena J.M.M. Mertens, Orbis Medical Center, Sittard; Willem E. Nolting, St Jans Hospital, Weert; Johannes J. van Beek, VieCuri Hospital, Venlo and Venray; Jan A. Roukema, Tilburg University and Elisabeth-TweeSteden Hospital Tilburg; and Roy F.P.M. Kruitwagen, Maastricht University Medical Center, Maastricht, the Netherlands. l.vd.poll@uvt.nl.
Abstract
PURPOSE: This study was conducted to longitudinally assess the impact of an automatically generated survivorship care plan (SCP) on patient-reported outcomes in routine clinical practice. Primary outcomes were patient satisfaction with information and care. Secondary outcomes included illness perceptions and health care use. METHODS:Twelve hospitals were randomly assigned to SCP care or usual care in a pragmatic, cluster randomized trial. Newly diagnosed patients with endometrial cancer completed questionnaires after diagnosis (n = 221; 75% response), 6 months (n = 158), and 12 months (n = 147). An SCP application was built in the Web-based ROGY (Registration System Oncological Gynecology). By clicking the SCP button, a patient-tailored SCP was generated. RESULTS: In the SCP care arm, 74% of patients received an SCP. They reported receiving more information about their treatment (mean [M] = 57, standard deviation [SD] = 20 v M = 47, SD = 24; P = .03), other services (M = 35, SD = 22 v M = 25, SD = 22; P = .03), and different places of care (M = 27, SD = 25 v M = 23, SD = 26; P = .04) than the usual care arm (scales, 0 to 100). However, there were no differences regarding satisfaction with information or care. Patients in the SCP care arm experienced more symptoms (M = 3.3, SD = 2.0 v M = 2.6, SD = 1.6; P = .03), were more concerned about their illness (M = 4.4, SD = 2.3 v M = 3.9, SD = 2.1; P = .03), were more affected emotionally (M = 4.0, SD = 2.2 v M = 3.7, SD = 2.2; P = .046), and reported more cancer-related contact with their primary care physician (M = 1.8, SD = 2.0 v M = 1.1, SD = 0.9; P = .003) than those in the usual care arm (scale, 1 to 10). These effects did not differ over time. CONCLUSION: The present trial showed no evidence of a benefit of SCPs on satisfaction with information and care. Furthermore, SCPs increased patients' concerns, emotional impact, experienced symptoms, and the amount of cancer-related contact with the primary care physician. Whether this may ultimately lead to more empowered patients should be investigated further.
RCT Entities:
PURPOSE: This study was conducted to longitudinally assess the impact of an automatically generated survivorship care plan (SCP) on patient-reported outcomes in routine clinical practice. Primary outcomes were patient satisfaction with information and care. Secondary outcomes included illness perceptions and health care use. METHODS: Twelve hospitals were randomly assigned to SCP care or usual care in a pragmatic, cluster randomized trial. Newly diagnosed patients with endometrial cancer completed questionnaires after diagnosis (n = 221; 75% response), 6 months (n = 158), and 12 months (n = 147). An SCP application was built in the Web-based ROGY (Registration System Oncological Gynecology). By clicking the SCP button, a patient-tailored SCP was generated. RESULTS: In the SCP care arm, 74% of patients received an SCP. They reported receiving more information about their treatment (mean [M] = 57, standard deviation [SD] = 20 v M = 47, SD = 24; P = .03), other services (M = 35, SD = 22 v M = 25, SD = 22; P = .03), and different places of care (M = 27, SD = 25 v M = 23, SD = 26; P = .04) than the usual care arm (scales, 0 to 100). However, there were no differences regarding satisfaction with information or care. Patients in the SCP care arm experienced more symptoms (M = 3.3, SD = 2.0 v M = 2.6, SD = 1.6; P = .03), were more concerned about their illness (M = 4.4, SD = 2.3 v M = 3.9, SD = 2.1; P = .03), were more affected emotionally (M = 4.0, SD = 2.2 v M = 3.7, SD = 2.2; P = .046), and reported more cancer-related contact with their primary care physician (M = 1.8, SD = 2.0 v M = 1.1, SD = 0.9; P = .003) than those in the usual care arm (scale, 1 to 10). These effects did not differ over time. CONCLUSION: The present trial showed no evidence of a benefit of SCPs on satisfaction with information and care. Furthermore, SCPs increased patients' concerns, emotional impact, experienced symptoms, and the amount of cancer-related contact with the primary care physician. Whether this may ultimately lead to more empowered patients should be investigated further.
Authors: Belle H de Rooij; Elyse R Park; Giselle K Perez; Julia Rabin; Katharine M Quain; Don S Dizon; Kathryn E Post; Garrett M Chinn; Allison L McDonough; Rachel B Jimenez; Lonneke V van de Poll-Franse; Jeffrey Peppercorn Journal: Oncologist Date: 2018-05-08
Authors: Melissa S Y Thong; Floortje Mols; Adrian A Kaptein; Dorry Boll; Caroline Vos; Johanna M A Pijnenborg; Lonneke V van de Poll-Franse; Nicole P M Ezendam Journal: Support Care Cancer Date: 2018-09-13 Impact factor: 3.603
Authors: Sarah A Birken; Alecia S Clary; Shampa Bernstein; Jamiyla Bolton; Miriam Tardif-Douglin; Deborah K Mayer; Allison M Deal; Sara R Jacobs Journal: J Oncol Pract Date: 2018-07-13 Impact factor: 3.840
Authors: Sarah A Birken; Sarah Raskin; Yuqing Zhang; Gema Lane; Alexandra Zizzi; Mandi Pratt-Chapman Journal: J Cancer Educ Date: 2019-06 Impact factor: 2.037
Authors: H Irene Su; Shaylyn Stark; Brian Kwan; Sarah Boles; Diana Chingos; Jennifer Ehren; Jessica R Gorman; Michael Krychman; Sally A D Romero; Jun J Mao; John P Pierce; Loki Natarajan Journal: Breast Cancer Res Treat Date: 2019-05-03 Impact factor: 4.872
Authors: Simon J Craddock Lee; Mark A Clark; John V Cox; Burton M Needles; Carole Seigel; Bijal A Balasubramanian Journal: J Oncol Pract Date: 2016-10-31 Impact factor: 3.840
Authors: Amye J Tevaarwerk; Jennifer R Klemp; Gijsberta J van Londen; Bradford W Hesse; Mary E Sesto Journal: Cancer Date: 2018-09-12 Impact factor: 6.860
Authors: Judith A Meiklejohn; Alexander Mimery; Jennifer H Martin; Ross Bailie; Gail Garvey; Euan T Walpole; Jon Adams; Daniel Williamson; Patricia C Valery Journal: J Cancer Surviv Date: 2016-05-02 Impact factor: 4.442